Sacubitril-Valsartan for Heart Failure: From Devil's Advocate to Evidence-Based Medicine

Affiliations

Editorial

Dragos Vinereanu. Am J Ther. 2017 Mar/Apr.

. 2017 Mar/Apr;24(2):e109-e110.

doi: 10.1097/MJT.0000000000000571.

¹ University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania.

No abstract available

Comment on

Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Clinical Trial.
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. Yandrapalli S, et al. Am J Ther. 2017 Mar/Apr;24(2):e234-e239. doi: 10.1097/MJT.0000000000000473. Am J Ther. 2017. PMID: 27574931